Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Covid-19 (회복)로 병원에 입원 한 환자의 Casirivimab 및 Imdevimab : 무작위, 통제, 오픈 라벨, 플랫폼 시험
Randomized Controlled Trial
Published on
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제,
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제,
[키워드] (Medical Research Council
1:1
28-day mortality
95% CI
Administered
Adverse reaction
Adverse reactions
All participants
all randomly assigned patients
all-cause mortality
Analysis
antibody
assigned
baseline
baseline antibody status
bleeding
Cardiac arrhythmia
Casirivimab
cause-specific mortality
clinically suspected
Combination
death
detectable
died
dose
Efficacy
Efficacy and safety
eligible
Eligible participants
enrolled
evaluate
finding
funding
hospital
host cells
humoral immune response
Imdevimab
Innovation
Intention
intention to treat
intravenous infusion
investigator
investigators
ISRCTN
laboratory-confirmed SARS-CoV-2 infection
Local
major bleeding events
Medical Research Council
monoclonal antibody
monoclonal antibody combination
Mortality
mounted
non-competing monoclonal antibodies
non-competing monoclonal antibody
Open-label
outcome
p value
participant
Patient
Platform trial
Primary outcome
randomisation
randomised
randomised, controlled, open-label platform trial
Randomly
randomly assigned patient
rate ratio
Receptor binding domain
recovery
reduced
Registered
reported
Safety
SARS-COV-2 infection
SARS-CoV-2 spike glycoprotein
SARS-CoV-2 vaccine
Serious adverse reactions
seronegative
seronegative patient
seronegative patients
seropositive
seropositive and seronegative patients
Seven
significantly
single intravenous infusion
spike glycoprotein
Standard of care
the SARS-CoV-2
thrombosis
Treatment
Trial
UK hospital
usual care
usual care alone
Viral
viral entry
with COVID-19
[DOI] 10.1016/S0140-6736(22)00163-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/S0140-6736(22)00163-5 PMC 바로가기 [Article Type] Randomized Controlled Trial